Skip Navigation

European Heart Journal 1995 16(Supplement L):81-85; doi:10.1093/eurheartj/16.suppl_L.81
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by van Hout, B. A.
Right arrow Articles by Simoons, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Hout, B. A.
Right arrow Articles by Simoons, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Scociety of Cardiology

Costs and effects of c7E3 in high risk PTCA patients

An indirect analysis for The Netherlands

B. A. van Hout and M. L. Simoons

Institute for Medical Technology Assessment, Erasmus University Rotterdam The Netherlands

Correspondence: Ben A. van Hout, Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands

A cost effectiveness study is presented on the use of c7E3 in high risk patients undergoing percutaneous coronary angioplasty (PTCA). The results from the EPIC study have been combined with cost data from The Netherlands.

The study took account of the number of survivors without ischaemic events, and the number with neither ischaemic events nor bleeding (both measured after 6 months). It is estimated that the initial costs of c7E3 and the additional costs due to the increased risk of bleeding are almost entirely counterbalanced by the savings, as a result of fewer myocardial infarctions and revascularizations. The additional costs per additional patient without ischaemic events are approximately DFL 5235. The additional costs per additional patient with neither ischaemic events nor bleeding are estimated at DFL 15 685. Both figures are less than the average for similar procedures without c7E3. Sensitivity analysis supports the conclusion that c7E3 treatment is efficient. However, cost effectiveness could be further improved if patients are carefully selected.

Key Words: Cost effectiveness • monoclonal antibody • c7E3 • PTCA


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
J.E.F Zwart-van Rijkom and B.A van Hout
Cost-efficacy in interventional cardiology; results from the EPISTENT study
Eur. Heart J., August 2, 2001; 22(16): 1476 - 1484.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
D. Hasdai, A. Lerman, D. E. Grill, C. S. Rihal, and D. R. Holmes Jr.
Medical Therapy after Successful Percutaneous Coronary Revascularization
Ann Intern Med, January 19, 1999; 130(2): 108 - 115.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.